(Q86335209)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23475757%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

title

Histone deacetylase inhibitors in the treatment for multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23475757%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1 reference

2

Kenneth C Anderson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23475757%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

author name string

Teru Hideshima

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23475757%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

publication date

10 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23475757%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Hematology

25 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23475757%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

volume

97

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23475757%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23475757%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

page(s)

324-332

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23475757%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12185-013-1290-3

25 February 2020

exact match

0 references

cites work

Suberoylanilide hydroxamic acid as a radiosensitizer through modulation of RAD51 protein and inhibition of homology-directed repair in multiple myeloma

1 reference

12 December 2020

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

1 reference

12 December 2020

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

1 reference

12 December 2020

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma

1 reference

12 December 2020

Hassles with taking out the garbage: aggravating aggresomes.

1 reference

12 December 2020

Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101.

1 reference

12 December 2020

Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid

1 reference

12 December 2020

Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors

1 reference

12 December 2020

Class II histone deacetylases: versatile regulators

1 reference

12 December 2020

Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.

1 reference

12 December 2020

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

1 reference

12 December 2020

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

1 reference

12 December 2020

The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells

1 reference

12 December 2020

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

1 reference

12 December 2020

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

1 reference

12 December 2020

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms

1 reference

12 December 2020

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

1 reference

12 December 2020

Histones and histone modifications

1 reference

12 December 2020

CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity

1 reference

12 December 2020

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

1 reference

12 December 2020

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

1 reference

12 December 2020

Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176).

1 reference

12 December 2020

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

1 reference

12 December 2020

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

1 reference

12 December 2020

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

1 reference

12 December 2020

The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress

1 reference

12 December 2020

Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma

1 reference

12 December 2020

A phase II study of depsipeptide in refractory metastatic renal cell cancer

1 reference

12 December 2020

In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines.

1 reference

12 December 2020

N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).

1 reference

12 December 2020

A review of depsipeptide and other histone deacetylase inhibitors in clinical trials

1 reference

12 December 2020

Chemical phylogenetics of histone deacetylases

1 reference

12 December 2020

Lysine acetylation targets protein complexes and co-regulates major cellular functions

1 reference

12 December 2020

Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824.

1 reference

12 December 2020

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

1 reference

12 December 2020

Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma

1 reference

12 December 2020

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

1 reference

12 December 2020

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells

1 reference

12 December 2020

Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice

1 reference

12 December 2020

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

1 reference

12 December 2020

Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer

1 reference

12 December 2020

Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation

1 reference

12 December 2020

FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities

1 reference

12 December 2020

Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma

1 reference

12 December 2020

Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.

1 reference

12 December 2020

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

1 reference

12 December 2020

The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy.

1 reference

12 December 2020